Key TakeawaysRoche announced strong early stage data from its weight-loss drug CT-996.The once-daily pill delivered placebo-adjusted mean weight loss of 6.1% in obesity patients without diabetes.CT-996 represent possible competition to popular weight-loss drugs Novo Nordisk's Wegovy and Eli Lilly's Zepbound. A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Nov ...